Hybrigenics receives clearance and funding for inecalcitol in psoriasis
This article was originally published in Scrip
Hybrigenics has received a zero interest loan of €650,000 from OSEO, the French financial institution supporting innovation, to cover 45% of the costs of a Phase II study with oral inecalcitol in patients with moderate-to-severe psoriasis. AFSSAPS, the French drug agency, recently granted authorisation for the trial to proceed.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.